clinical trial · NCT07890415
Using an Artificial Intelligence (AI) Tool for Melanoma Diagnosis
Malignant Melanoma of SkinOther and Unspecified Malignant Neoplasm of SkinMelanoma in SituCarcinoma in Situ of SkinHemangiomaMelanocytic NeviOther Benign Neoplasms of SkinNeoplasm of Uncertain Behavior of SkinClinical decision support tool
brief summary
The purpose of this study is to learn whether a computer-based support tool called DEXI (Dermoscopy EXplainable Intelligence) can help dermatologists decide whether a lesion may be melanoma, a serious type of skin cancer. DEXI uses artificial intelligence, or AI, which means computer technology that looks for patterns in images and information. DEXI works within a software program called the DermaGraphix Visualizer, which displays and organizes skin and lesion images. The goal of this study is to see whether DEXI can help doctors find melanoma and reduce biopsies that may not be needed.
started
Oct 15, 2026
primary completion
Oct 15, 2029
completion
Oct 15, 2029
last updated
Oct 22, 2026
official title
Pragmatic Randomized Controlled Trial of Artificial Intelligence for Melanoma Diagnosis (PRACTA-MEL) (AI)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol